Equities Analysts Issue Forecasts for Moderna FY2029 Earnings

Moderna, Inc. (NASDAQ:MRNAFree Report) – Analysts at Brookline Capital Management issued their FY2029 earnings per share estimates for Moderna in a research report issued on Monday, January 13th. Brookline Capital Management analyst L. Cann expects that the company will earn $22.02 per share for the year. The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share.

A number of other equities research analysts have also issued reports on MRNA. Berenberg Bank began coverage on shares of Moderna in a report on Tuesday, November 19th. They set a “hold” rating and a $42.00 target price on the stock. Wolfe Research initiated coverage on Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective on the stock. UBS Group decreased their target price on Moderna from $108.00 to $96.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Finally, Sanford C. Bernstein began coverage on Moderna in a research report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price target on the stock. Four research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $76.68.

Get Our Latest Stock Analysis on MRNA

Moderna Stock Up 0.9 %

Shares of MRNA opened at $34.77 on Wednesday. The company’s 50-day simple moving average is $41.44 and its 200-day simple moving average is $67.56. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. Moderna has a 1 year low of $31.94 and a 1 year high of $170.47. The stock has a market capitalization of $13.38 billion, a PE ratio of -5.97 and a beta of 1.60.

Moderna (NASDAQ:MRNAGet Free Report) last announced its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. Moderna’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period last year, the business posted ($1.39) EPS.

Hedge Funds Weigh In On Moderna

A number of hedge funds have recently modified their holdings of MRNA. Axiom Advisory LLC boosted its stake in Moderna by 1.6% during the 3rd quarter. Axiom Advisory LLC now owns 12,672 shares of the company’s stock worth $847,000 after purchasing an additional 198 shares during the period. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Moderna during the second quarter worth about $26,000. Arkadios Wealth Advisors boosted its stake in shares of Moderna by 2.2% during the third quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock worth $764,000 after buying an additional 243 shares during the period. Knuff & Co LLC grew its holdings in shares of Moderna by 5.4% during the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after buying an additional 244 shares during the last quarter. Finally, Stephens Inc. AR increased its position in Moderna by 7.9% in the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock valued at $223,000 after acquiring an additional 245 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold 2,664 shares of company stock worth $115,210 in the last ninety days. 15.70% of the stock is owned by corporate insiders.

About Moderna

(Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Further Reading

Earnings History and Estimates for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.